Skip to main content

A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

Active, not recruiting · Phase 3 · NCT04170283

Conditions: B-cell Malignancies

At a glance

Research payments reported, 2025
$12.0M
U.S. investigators named
29
Sites paid
29
Planned or actual enrollment
955

About the trial

Sponsor
BeOne Medicines
Tested
Zanubrutinib (drug), Tislelizumab (drug)
Dates
Started 2020-01-16; completion 2026-12-31
Results posted
Not yet

The purpose of this study is to learn about the long-term safety and effectiveness of zanubrutinib in people with B-cell cancers who took part in an earlier zanubrutinib study. Participants continued receiving zanubrutinib if they were still benefiting from it, or they might have taken part in long-term follow-up after treatment. Information collected in this study will help health authorities better understand the long-term effects of zanubrutinib.

From ClinicalTrials.gov, last updated 2026-08-28. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Beone Medicines Ltd. reported $12.0M in research payments for this study in 2025 (528 payments).

Products named: Brukinsa

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Ut MD Anderson Cancer Center $2.1M
  • Dana-Farber Cancer Institute $1.1M
  • Mayo Clinic Scottsdale $1.0M
  • Florida Cancer Specialist (scri) - Fort Myers $871,164
  • Willamette Valley Cancer Insti $786,000
  • Clinical Research Alliance, Inc. $645,198
  • Central Arkansas Radiation Therapy Institute, Inc $615,110
  • Ohsu Hospital and Clinics, OR $560,420
  • Oncology and Hematology Associates of Southwest Virginia Inc $555,055
  • Uso Texas Oncology $469,600
  • Florida Cancer Specialists & Research Institute, LLC $387,760
  • Summit Medical Group $377,280
  • Fred Hutchinson Cancer Center $356,320
  • Duke University , $346,364
  • Rocky Mountain Cancer Centers $335,360
  • Morristown Medical Center, NJ $288,951
  • University of Michigan Health System, MI $284,311
  • Forrest General Hospital Cancer Center $262,000
  • The University of Nebraska Medical Cente R / Cente $209,600
  • Comprehensive Cancer Centers of Nevada - Central Valley $163,610
  • The Sarah Cannon Research Institute, Tennessee Oncology, PLLC $79,055
  • University of kansas medical center research institute, inc. $52,400
  • University of Washington Medical Ctr, WA $36,341
  • Banner Casa Grande Medical Center, AZ $32,009
  • Dana Farber Mass General Brigham Cancer Care Inc $22,739
  • Medical Oncology Associates, Ps $15,297
  • Hattiesburg Hematology and Oncology Clinic $10,982
  • Summit Medical Group, P.a. $10,372
  • University of Nebraska $6,566

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.